[go: up one dir, main page]

PE20020770A1 - Formulaciones de entecavir de dosis bajas y uso - Google Patents

Formulaciones de entecavir de dosis bajas y uso

Info

Publication number
PE20020770A1
PE20020770A1 PE2001000552A PE2001000552A PE20020770A1 PE 20020770 A1 PE20020770 A1 PE 20020770A1 PE 2001000552 A PE2001000552 A PE 2001000552A PE 2001000552 A PE2001000552 A PE 2001000552A PE 20020770 A1 PE20020770 A1 PE 20020770A1
Authority
PE
Peru
Prior art keywords
entecavir
low dose
dextrosphate
use formulations
calcium
Prior art date
Application number
PE2001000552A
Other languages
English (en)
Inventor
Richard J Colonno
Divyakant Desai
Omar L Sprockel
Abizer Harianawala
Michael G Fakes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020770(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20020770A1 publication Critical patent/PE20020770A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS B QUE COMPRENDE: a) DE 0.001 mg A 25 mg DE ENTECAVIR Y b) UN PORTADOR FARMACEUTICAMENTE ACEPTABLE SELECCIONADO DE LACTOSA, CELULOSA MICROCRISTALINA, FOSFATO DE CALCIO, DEXTRINA, DEXTROSA, ENTRE OTROS. EL ENTECAVIR [1S-(1O,3O,4ß)]-2-AMINO-1,9-DIHIDRO-9-[4-HIDROXI-3-(HIDROXIMETIL)-2-METILENCICLOPENTIL]-6H-PURIN-6-ONA SE ADHIERE A DICHO SUBSTRATO POR UNA SUBSTANCIA ADHESIVA LA CUAL ES UN MATERIAL POLIMERICO QUE POSEE SUFICIENTE VISCOSIDAD Y ES SELECCIONADA DE POVIDONA, METILCELULOSA, HIDROXIMETILCELULOSA, ENTRE OTROS. LA COMPOSICION INCLUYE ADEMAS UN LUBRICANTE Y UN DESINTEGRANTE. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION
PE2001000552A 2000-02-29 2001-06-12 Formulaciones de entecavir de dosis bajas y uso PE20020770A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28

Publications (1)

Publication Number Publication Date
PE20020770A1 true PE20020770A1 (es) 2002-09-06

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000552A PE20020770A1 (es) 2000-02-29 2001-06-12 Formulaciones de entecavir de dosis bajas y uso

Country Status (35)

Country Link
US (1) US6627224B2 (es)
EP (2) EP1642582A1 (es)
JP (3) JP5140222B2 (es)
KR (1) KR100757155B1 (es)
AR (1) AR027965A1 (es)
AT (1) ATE312613T1 (es)
AU (1) AU2001229775A1 (es)
BG (1) BG65815B1 (es)
BR (1) BRPI0108435B8 (es)
CA (1) CA2401569C (es)
CO (1) CO5261593A1 (es)
CZ (1) CZ303395B6 (es)
DE (1) DE60115870T3 (es)
DK (1) DK1267880T4 (es)
EA (1) EA006181B1 (es)
EE (1) EE05442B1 (es)
EG (1) EG24408A (es)
ES (1) ES2253403T5 (es)
GE (1) GEP20053504B (es)
HK (1) HK1048771A1 (es)
HR (1) HRP20020649A2 (es)
HU (1) HU230698B1 (es)
IL (1) IL150447A0 (es)
MX (1) MXPA02008359A (es)
MY (1) MY127422A (es)
NO (1) NO324014B1 (es)
NZ (1) NZ520024A (es)
PE (1) PE20020770A1 (es)
PL (1) PL201411B1 (es)
RS (1) RS51561B (es)
SI (1) SI1267880T2 (es)
SK (1) SK288008B6 (es)
TW (1) TWI287988B (es)
UA (1) UA84534C2 (es)
WO (1) WO2001064221A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH061291Y2 (ja) 1988-03-04 1994-01-12 株式会社日立工機原町 拘束状態解除装置付き丸鋸式切断機
CA2401569C (en) * 2000-02-29 2009-08-18 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ES2397104T3 (es) 2002-12-11 2013-03-04 Bristol-Myers Squibb Company Procedimiento y productos intermedios para la síntesis de entecavir
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
HUE029533T2 (en) 2003-11-17 2017-03-28 Biomarin Pharm Inc Treatment of phenylketonuria with BH4
EP1686965A2 (de) * 2003-11-18 2006-08-09 Boehringer Ingelheim International GmbH Feste pharmazeutische zubereitungsform
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
WO2006034397A2 (en) * 2004-09-23 2006-03-30 Fmc Corporation Coating composition
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
BR112012010170A2 (pt) * 2009-10-28 2016-04-12 Mcneil Ppc Inc composições de revestimento para desintegração/dissolução rápida
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
EA201290556A1 (ru) 2009-12-23 2013-01-30 Рациофарм Гмбх Оральная лекарственная форма, включающая энтекавир
EP2536411A4 (en) 2010-02-18 2013-08-07 Univ Princeton HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM
CN106008570A (zh) 2010-03-31 2016-10-12 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
EP2606895A4 (en) * 2010-10-12 2014-04-02 Univ Wuhan PLASTER FOR THE TRANSDERMAL ABSORPTION OF AN ANTIVIRUS ACTIVE SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
US20140315930A1 (en) * 2011-11-14 2014-10-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
SG11201610636VA (en) * 2014-06-20 2017-01-27 Ctc Bio Inc Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
JP6625878B2 (ja) * 2015-01-26 2019-12-25 沢井製薬株式会社 エンテカビル含有錠剤、その製造方法及びそれを用いた口腔内崩壊錠
WO2017057147A1 (ja) 2015-09-30 2017-04-06 株式会社ダイセル 易服用性固形製剤用粒子組成物及び該粒子組成物を含む易服用性固形製剤
CA3155068A1 (en) * 2019-09-29 2021-04-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination containing tlr7 agonist
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
DK0929294T3 (da) * 1996-04-04 2003-09-29 Felix Specht Fremgangsmåde til fremstilling af lavt doserede fritflydende og/eller direkte komprimerbare pulversystemer
AU4090697A (en) 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
CA2401569C (en) * 2000-02-29 2009-08-18 Bristol-Myers Squibb Company Low dose entecavir formulation and use

Also Published As

Publication number Publication date
EA200200812A1 (ru) 2003-12-25
PL201411B1 (pl) 2009-04-30
JP2012255017A (ja) 2012-12-27
HRP20020649A2 (en) 2004-12-31
AR027965A1 (es) 2003-04-16
DK1267880T3 (da) 2006-03-06
BR0108435A (pt) 2004-06-15
JP2015178523A (ja) 2015-10-08
HU230698B1 (hu) 2017-09-28
BRPI0108435B8 (pt) 2021-05-25
EP1642582A1 (en) 2006-04-05
SK288008B6 (sk) 2012-10-02
DK1267880T4 (da) 2010-05-17
TWI287988B (en) 2007-10-11
CA2401569C (en) 2009-08-18
EP1267880A1 (en) 2003-01-02
CA2401569A1 (en) 2001-09-07
PL366102A1 (en) 2005-01-24
BG106905A (bg) 2003-04-30
BG65815B1 (bg) 2010-01-29
CO5261593A1 (es) 2003-03-31
HUP0500558A3 (en) 2012-08-28
EG24408A (en) 2009-05-20
DE60115870T3 (de) 2010-07-29
WO2001064221A1 (en) 2001-09-07
EE200200484A (et) 2004-04-15
JP5140222B2 (ja) 2013-02-06
NO324014B1 (no) 2007-07-30
ES2253403T3 (es) 2006-06-01
HK1048771A1 (zh) 2003-04-17
IL150447A0 (en) 2002-12-01
CZ303395B6 (cs) 2012-08-29
KR20020082230A (ko) 2002-10-30
MXPA02008359A (es) 2003-02-12
GEP20053504B (en) 2005-05-10
YU63002A (sh) 2005-03-15
SI1267880T2 (sl) 2010-04-30
KR100757155B1 (ko) 2007-09-07
RS51561B (sr) 2011-08-31
EE05442B1 (et) 2011-08-15
EP1267880B2 (en) 2010-01-20
SK11652002A3 (sk) 2003-09-11
US6627224B2 (en) 2003-09-30
NZ520024A (en) 2005-03-24
EA006181B1 (ru) 2005-10-27
DE60115870D1 (de) 2006-01-19
JP2004503467A (ja) 2004-02-05
US20010033864A1 (en) 2001-10-25
MY127422A (en) 2006-11-30
NO20024099D0 (no) 2002-08-28
BRPI0108435B1 (pt) 2019-02-05
UA84534C2 (uk) 2008-11-10
DE60115870T2 (de) 2006-08-17
SI1267880T1 (sl) 2006-06-30
NO20024099L (no) 2002-08-28
AU2001229775A1 (en) 2001-09-12
HUP0500558A2 (hu) 2005-09-28
ATE312613T1 (de) 2005-12-15
ES2253403T5 (es) 2010-04-22
JP5921746B2 (ja) 2016-05-24
EP1267880B1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
PE20020770A1 (es) Formulaciones de entecavir de dosis bajas y uso
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
SE8804629D0 (sv) New therapeutically active compounds
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
MA27285A1 (fr) COMBINAISON D'AZELASTINE ET DE STEROiDES
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
RU2011131532A (ru) Способ лечения бессонницы
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca

Legal Events

Date Code Title Description
FC Refusal